Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ATAI
ATAI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATAI News
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
2d ago
Yahoo Finance
Trump Administration to Examine Ibogaine Research for PTSD Funding
3d ago
stocktwits
Trump Plans Executive Order to Boost Psychedelic Research
4d ago
seekingalpha
AtaiBeckley to Participate in Healthcare Conferences
6d ago
Newsfilter
AtaiBeckley Reports Promising Phase 2a Data for BPL-003 in Treatment-Resistant Depression
Apr 08 2026
NASDAQ.COM
AtaiBeckley Reports Positive Phase 2a Results for BPL-003 in Treatment-Resistant Depression
Apr 08 2026
Newsfilter
Deutsche Bank Sees AtaiBeckley as a Leader in Psychedelic Renaissance
Mar 29 2026
CNBC
Wall Street's Latest Ratings Overview
Mar 27 2026
CNBC
ATAIBECKLEY INC: DEUTSCHE BANK STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $12
Mar 27 2026
moomoo
AtaiBeckley Inc. Gains Bullish Support from H.C. Wainwright
Mar 27 2026
Yahoo Finance
AtaiBeckley Reports Positive Phase 2a Results for BPL-003 in Treatment-Resistant Depression
Mar 17 2026
seekingalpha
Atai Beckley Analysts Maintain Buy Ratings with $14 Price Target
Mar 10 2026
Benzinga
AtaiBeckley Advances BPL-003 Treatment Plan
Mar 10 2026
Newsfilter
Helus Pharma Advances New Drug for Anxiety Treatment
Mar 09 2026
Newsfilter
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
Mar 09 2026
PRnewswire
AtaiBeckley Explores Strategic Options for BPL-003
Mar 07 2026
seekingalpha
Show More News
